ARTICLE | Clinical News
CEGE starts Phase II GVAX AML study
November 27, 2001 8:00 AM UTC
Cell Genesys (CEGE) began a U.S. Phase II trial of GVAX cancer vaccine in combination with bone marrow transplantation in 50 patients with acute myelogenous leukemia (AML). Patients will undergo chemo...